No connection

Search Results

LLY vs PIII

LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%
PIII
P3 Health Partners Inc.
BEARISH
Price
$2.50
Market Cap
$507.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
LLY
41.7
PIII
--
Forward P/E
LLY
22.78
PIII
-11.9
P/B Ratio
LLY
32.33
PIII
-0.05
P/S Ratio
LLY
13.16
PIII
0.35
EV/EBITDA
LLY
27.08
PIII
-1.53

Profitability

Gross Margin
LLY
83.04%
PIII
-4.12%
Operating Margin
LLY
44.9%
PIII
-39.98%
Profit Margin
LLY
31.67%
PIII
-10.14%
ROE
LLY
101.16%
PIII
-6952.57%
ROA
LLY
19.41%
PIII
-23.46%

Growth

Revenue Growth
LLY
42.6%
PIII
3.8%
Earnings Growth
LLY
51.4%
PIII
--

Financial Health

Debt/Equity
LLY
1.65
PIII
--
Current Ratio
LLY
1.58
PIII
0.24
Quick Ratio
LLY
0.78
PIII
0.22

Dividends

Dividend Yield
LLY
0.68%
PIII
--
Payout Ratio
LLY
26.14%
PIII
0.0%

AI Verdict

LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)
PIII BEARISH

P3 Health Partners exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic balance sheet metrics. The company is operating with negative equity (Price/Book: -0.05) and a critical liquidity crisis, evidenced by a Current Ratio of 0.24. Massive operating losses and a staggering ROE of -6952.57% indicate a failing business model. With a 5-year price decline of 99.5% and consistent earnings misses, the company faces significant insolvency risk.

Strengths
Low Price-to-Sales ratio (0.35) suggests low valuation relative to revenue
Marginal positive revenue growth (3.80% YoY)
Analyst target price ($3.50) sits above current market price
Risks
Critical liquidity shortage with a Current Ratio of 0.24
Negative shareholder equity (Price/Book -0.05)
Extreme operational inefficiency with -39.98% operating margins

Compare Another Pair

LLY vs PIII: Head-to-Head Comparison

This page compares Eli Lilly and Company (LLY) and P3 Health Partners Inc. (PIII) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile